BofA Securities Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Maintains Target Price $14
Buy Rating for Meiragtx Holdings: Promising Secondary Endpoint Results and Regulatory Optimism Drive Confidence
MeiraGTx Holdings Is Maintained at Outperform by RBC Capital
MeiraGTx Hldgs Analyst Ratings
RBC Raises Price Target on MeiraGTx Holdings to $13 From $11, Keeps Outperform, Speculative Risk
BofA Securities Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Raises Target Price to $14
Bank of America Securities Sticks to Their Buy Rating for Meiragtx Holdings (MGTX)
Piper Sandler Initiates MeiraGTx Holdings(MGTX.US) With Buy Rating, Announces Target Price $26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Oculis Holding (OCS) and Meiragtx Holdings (MGTX)
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Maintains $36 Price Target
MeiraGTx Hldgs Analyst Ratings
MeiraGTx Holdings Is Maintained at Outperform by RBC Capital
MeiraGTx Hldgs Analyst Ratings
RBC Capital Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Raises Target Price to $11
BofA Securities Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Cuts Target Price to $12
MeiraGTx Hldgs Analyst Ratings
RBC Capital Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Cuts Target Price to $9
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)
MeiraGTx Holdings Price Target Announced at $36.00/Share by Chardan Capital
MeiraGTx Hldgs Analyst Ratings